Fazekas Tamás, Merkely Béla, Papp Gyula, Tenczer József (szerk.)

Klinikai szív-elektrofiziológia és aritmológia


Irodalom

  1. Abi-Gerges, N. , Small, B. G., Lawrence, C. L. et al.: Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br. J. Pharmacol., 2004, 142: 1255–1264.
  2. Abo, K., Ishida, Y., Yoshida, R. et al.: Torsade de pointes in NIDDM with long QT intervals. Diabetes Care, 1996, 19: 1010.
  3. Abrahamsson, C.: Proarrhythmias related to delayed repolarisation. Importance of dispersion of repolarisation and early afterdepolarisations. PhD Thesis, Göteborg, 1996, 1–70.
  4. Ackermann MJ: Unmasking concealed long QT syndrome. Heart Rhythm, 2008, 5: 8–10.
  5. Aiba, T., Shimizu, W., Inagaki, M. et al.: Cellular and ionic mechanism for drug-induced long-QT syndrome and effectiveness of verapamil. JACC, 2005, 45: 300–307.
  6. Aiba, T., Shimizu, W., Inagaki, M. et al.: Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. Pacing Clin. Electrophysiol., 2004, 27: 901–909.
  7. Akiyama, T. et al.: Hypocalcemic torsades de pointes. J. Electrocardiol, 1989, 22: 89–92.
  8. Andrássy, G., Szabó, A., Dunai, A. et al.: Heart rate correction of the QT interval during exercise. Card. Hung., 2005, 35: 17–20.
  9. Antimisiaris, M., Sarma, J. S., Schoenbaum, M. P. et al.: Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death. Am. Heart J., 1994, 128: 884–891.
  10. Antzelevitch, C.: Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace, 2007, 9(Suppl 4): 4–15,
  11. Antzelevitch, C.: Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm., 2005, 2: S9–S15.
  12. Antzelevitch, C., Belardinelli, L., Zygmunt, A. C. et al.: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation, 2004, 110: 904–910.
  13. Antzelevitch, C., Oliva, A.: Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J. Int. Med., 2005, 259: 48–58.
  14. Antzelevitch, C., Shimizu, W., Yan, G. X. et al.: The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol., 1999, 10: 1124–1152.
  15. Antzelevitch, C., Sicouri, S.: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and Torsades de Pointes. J. Am. Coll. Cardiol., 1994, 23: 259–277.
  16. Antzelevitch, C., Sun, Z. Q., Zhang, Z. Q. et al.: Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J. Am. Coll. Cardiol., 1996, 28: 1836–1848.
  17. Assmann, I., Müller, E.: Prognostic significance of different QT-intervals in the body surface ECG in patients with acute myocardial infarction and in patients with acute or chronic cerebral processes. Acta Cardiol., 1990, 45: 501–504.
  18. Balaji, S., Sethuraman, K. R., Sundararaman, T.: Hypomagnesemia with hypokalemia in an uncontrolled diabetic patient presenting with recurrent episodes of torsades de pointes. J. Assoc. Physicians India, 1999, 47: 645–646.
  19. Baláti, B., Varró, A., Papp, J. Gy.: Comparison of the cellular electrophysiological characteristics of canine left ventricular epicardium, M cells, endocardium and Purkinje fibres. Acta Physiol. Scand., 1998, 164: 181–190.
  20. Barlow, J. B., Obel, I. W., Pocock, W. A. et al.: Sotalol: a unique Class III antiarrhythmic agent. Am. J. Cardiol., 1994, 73: 932–933.
  21. Batchvarov, V. N., Ghuran, A., Smetana, P. et al.: QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am. J. Physiol. Heart Circ. Physiol., 2002, 282: H2356–H2363.
  22. Bauman, J. L., Bauernfeind, R. A., Hoff, J. V. et al.: Torsade de pointes due to quinidine: Observations in 31 patients. Am. Heart J., 1984, 107: 425–430.
  23. Bayer, R., Schwarzmayer, J., Pernice, R.: Basic mechanisms underlying prenylamine-induced “torsades de pointes”: differences between prenylamine and fendiline due to basic actions of the isomers. Curr. Med. Res. Opin., 1988, 11: 254–272.
  24. Bayes, de Luna A., Guindo, J., Elosua, R. et al.: Proarrhythmic effects of anti-arrhythmic agents. Postgrad. Med. J., 1994, 70 (Suppl 1): S84–S88.
  25. Bazett, H. C.: An analysis of the time-relations of electrocardiograms. Heart, 1920, 4: 353–370.
  26. Bednar, M. M., Harrigan, E. P., Ruskin, J. N.: Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am. J. Cardiol., 2002, 89: 1316–1319.
  27. Ben-David, J., Zipes, D. P.: Torsades de pointes and proarrhythmia. Lancet, 1993, 341: 1578–1582.
  28. Berger, R. D.: QT variability. J. Electrocardiol., 2003, 36. Suppl: 83–87.
  29. Beyerbach, D. M., Kovacs, R. J., Dmitrienko, A. A. et al.: Heart rate-corrected QT interval in men increases during winter months. Heart Rhythm., 2007, 4: 277–81.
  30. Bezzina, C., Veldkamp, M. W., van der Berg, M. P. et al.: A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ. Res., 1999, 85: 1206–1213.
  31. Bonatti, V., Rolli, A., Botti, G.: Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur. Heart J., 1983, 4: 168–179.
  32. Boros, J.: A szív rytmus-zavarainak orvoslása chinidinnel. Orv. Hetil., 1922, 66: 71–73.; 83–85.
  33. Botstein, P: Is QT interval prolongation harmful? A regulatory perspective. Am. J. Cardiol., 1993, 72: 50B–52B.
  34. Bőhm, Á., Pintér, A., Préda, I.: Pacemaker induced torsades de pointes tachycardia. Heart, 1998, 80: 466.
  35. Brugada, P., Wellens, H. J. J.: Early afterdepolarizations: role in conduction block, “prolonged repolarization-dependent reexcitation,” and tachyarrhythmias in the human heart. Pacing Clin. Electrophysiol., 1985, 8: 889–896.
  36. Buday, G., Kerkovits, Gy., Sármán, P.: Kaotikus kamrai tachycardia és hyperaldosteronismus. Cardiol. Hung., 1987, 7: 83–89.
  37. Burashnikov, A., Antzelevitch, C.: β-adrenergic stimulation produces transient action potential prolongation in canine ventricular M cells but not in Purkinje, epicardial, or endocardial cells when the contribution of IKr is reduced. Pacing Clin. Electrophysiol., 1996, 19: 639A.
  38. Burashnikov, A., Antzelevitch, C.: Mechanism of acceleration-induced early afterdepolarization activity and action potential prolongation in tissues isolated from the M region of the canine ventricle. Pacing Clin. Electrophysiol., 1996, 19: 645A.
  39. Büky, B.: Effect of magnesium on ventricular fibrillation due to hypothermia. Br. J. Anaesth., 1970, 42: 886.
  40. Camm, A. J., Malik, M., Yap, Y. G.: Measurement of QT interval and repolarization assessment. In: Acquired long QT syndrome. Camm, A. J., Malik, M., Yap, Y. G. (eds) Blackwell Publishing, Oxford, 2004, 24–59.
  41. Camm, A. J., Yap, Y. G., Malik, M.: Acquired long QT syndrome. Futura Publishing Co., Armonk, New York, 2004, 1–216.
  42. Carlsson, L., Abrahamsson, C., Andersson, B. et al.: Proarrhythmic effects of the Class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res., 1993, 27: 2186–2193.
  43. Carlsson, L., Almgren, O., Duker, G.: QTU-prolongation and torsades de pointes induced by putative Class III antiarrhythmic agents in the rabbit: Etiology and interventions. J. Cardiovasc. Pharmacol., 1990, 16: 276–285.
  44. Celik, T., Iyisoy, A., Kursaklioglu, H. et al.: QT dispersion: electrophysiological holy grail or the greatest fallacy in the surface ECG? Int. J. Cardiol., 2007, 117: 404–405.
  45. Chambers, J. B., Walton, R.T., Coupe, M. O. et al.: QT prolongation after ileojejunal bypass. Lancet., 1985, 2: 1308.
  46. Chinushi, M., Restivo, M., Caref, E. B., El-Sherif, N.: Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome. Tridimensional analysis of the kinetics of cardiac repolarization. Circ. Res., 1998, 83: 614–628.
  47. Cleland, J. G., Daubert, J. C., Erdmann, E.: Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur. Heart J., 2006, 27: 1928–1932.
  48. Cowan, J. C., Yusoff, K., Moore, M. et al.: Importance of lead selection in QT interval measurement. Am. J. Cardiol., 1988, 61: 83–87.
  49. D’Alnoncourt, C. N., Zierhut, W., Lüderitz, B.: „Torsade de pointes” tachycardia. Reentry or focal activity? Br. Heart J., 1982, 48: 213–216.
  50. Dany, F. et al.: Torsades de pointes arytmies ventriculaires graves par administration parentérale de vincamine. Arch. Mal. Coeur., 1979, 73(3): 298–306.
  51. Darbar, D., Harris, P. A., Hardy, A. et al.: Marked steepening of QT restitution following cardioversion of atrial fibrillation. Heart Rhythm., 2004, 1: S192.
  52. Darpö, B.: Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur. Heart J., 2001, 59 (Suppl. K): K70–K80.
  53. Darpö, B., Almgren, O.: Almokalant – a selective Class III antiarrhythmic compound. Cardiovasc. Drug. Rev., 1996, 14: 60–83.
  54. De Ponti, F., Poluzzi, E., Cavalli, A. et al.: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. An overview. Drug Safety, 2002, 25: 263–286.
  55. De Ponti, F., Poluzzi, E., Montanaro, N.: QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol., 2000, 56: 1–18.
  56. Denney, S. D., Lakkireddy, D. R., Khan, I. A.: Long QT syndrome and torsade de pointes in transient left ventricular apical ballooning syndrome. Int. J. Cardiol., 2005, 100: 499–501.
  57. Denvir, M. A., Sood, A., Dow, R.: Thioridazine, diarrhoea and torsades de pointe. J. R. Soc. Med., 1998, 91: 145–147.
  58. Dessertenne, F., Fabiato, A., Coumel, P.: A new chapter of electrocardiography: The progressive variations in the amplitude of the electrocardiogram. Cardiovasc. Drugs Ther., 1991, 5: 171–190. (az Actual Cardiol Angéiol Int-ben [4: 241–258, 1966] megjelent francia dolgozat fordítása)
  59. Drici, M. D., Barhanin, J.: Cardiac K+ channels and drug-acquired long QT syndrome. Therapie, 2000, 55: 185–193.
  60. Drici, M. D., Wang, W. X., Liu, X. K. et al.: Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J. Clin. Psychopharmacol., 1998, 18: 477–481.
  61. Drolet, B., Simard, C., Roden, D. M.: Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potasium currents. Circulation, 2004, 109: 26–29.
  62. Drolet, B., Zhang, S., Deschenes, D. et al.: Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol., 1999, 10: 1597–1604.
  63. El-Sherif, N., Caref, E. B., Yin, H. et al.: The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ. Res., 1996, 79: 474–492.
  64. El-Sherif, N., Chinushi, M., Caref, E. B. et al.: Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation, 1997, 96: 4392–4399.
  65. El-Sherif, N., Zeiler, R. H., Craelius, W. et al.: QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Circulation, 1988, 63: 286–305.
  66. Emori, T., Antzelevitch, C.: Cellular basis for complex T waves and arrhythmic activity following combined IKr and IKs block. J. Cardiovasc. Electrophysiol., 2001, 12: 1379–1380.
  67. Escande, D.: Pharmacogenetics of cardiac K+ channels. Eur. J. Pharmacol., 2000, 410: 281–287.
  68. Etheridge, S. P., Compton, S. J., Tristani-Firouzi, M. et al.: A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J. Am. Coll. Cardiol., 2003, 42: 1777–1782.
  69. Fabiato, A., Coumel, P.: Torsades de Pointes, a quarter of a century later: a tribute to Dr. F. Dessertenne. Cardiovasc. Drugs Ther., 1991, 5: 167–170.
  70. Facchini, M., Sala, L., Malfatto, G.: Low-K+ dependent QT prolongation and risk for ventricular arrhythmia in anorexia nervosa. Int. J. Cardiol., 2006, 106: 170–176.
  71. Faggiano, P., Gardini, A., D’Aloia, A. et al.: Torsade de pointes occurring early during oral amiodarone treatment. Int. J. Cardiol., 1996, 55: 205–208.
  72. Fazekas, T., Carlsson, L., Scherlag, B. J. et al.: Electrophysiological and inotropic characterization of a novel Class III antiarrhythmic agent, GLG-V 13, in the mammalian heart. J. Cardiovasc. Pharmacol., 1996, 28: 182–191.
  73. Fazekas, T., Csanádi, Z.: A szívritmuszavarok kezelése. Klinikai bizonyítékok. Medicina Könyvkiadó, Budapest, 2004, 1–358.
  74. Fazekas, T., Kiss, Z.: Adams–Stokes-syndromával járó paroxysmalis kamrai tachycardia Clinium-kezelés közben. Orv. Hetil., 1977, 118: 1051–1053.
  75. Fazekas, T., Kiss, Z.: Kamrai tachycardia “torsades de pointe” jelenséggel. Magy. Belorv. Arch., 1979, 32: 199–204.
  76. Fazekas, T., Krassói, I., Lengyel, Cs.: Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin. Electrophysiol., 1998, 21: 147–150.
  77. Fazekas, T., Liszkai, G.: Antiarrhythmiás és nem-szívérrendszeri gyógyszerek, valamint beültethető cardioverter-defibrillátorok által előidézett klinikai proarrhythmiák. Orv. Hetil., 2002, 143: 61–69.
  78. Fazekas, T., Liszkai, G.: Az EKG QT-időszakaszát megnyújtó nem antiarrhythmiás gyógyszerek ritmuszavarkeltő (torsadogen) hatása. Orv. Hetil., 2005, 146: 451–460.
  79. Fazekas, T., Liszkai, G.: Bradycardia-dependens, teljes atrioventricularis blokk talaján fellépő „torsades de pointes” kamrai tachycardia. Magy. Belorv. Arch., 2000, 53: 233–238.
  80. Fazekas, T., Liszkai, G., Rudas, L.: Elektrokardiográfiás Osborn-hullám hypothermiában. Orv. Hetil., 2000, 141: 2347–2351.
  81. Fazekas, T., Scherlag, B. J., Mabo, P. et al.: Facilitation of reentry by lidocaine in canine myocardial infarction. Am. Heart J., 1994, 127: 345–352.
  82. Fazekas, T., Scherlag, B. J., Vos, M. et al.: Magnesium and the heart. Antiarrhythmic therapy with magnesium. Clin. Cardiol., 1993, 16: 768–774.
  83. Fazekas, T., Smeets, J. L. R. M., Wellens, H. J. J.: Az antiaritmiás gyógyszerek aritmogén hatása. A proaritmiák korszerű klinikai szemlélete. Orv. Hetil., 1991, 132: 2243–2248.
  84. Fazekas, T., Szabó, B., Scherlag, B. J.: A hosszú QT/QTU-szindróma és a “torsades de pointes” kamrai tachycardia. Orvosképzés, 1993, 68: 99–111.
  85. Fazekas, T., Szilvássy, Z., Carlsson, L. et al.: Comparison of the proarrhythmic effect of GLG-V-13, a novel Class III antiarrhythmic compound, in two rabbit models of torsades de pointes ventricular tachycardia. Ann. Noninvasive Electrocardiol., 1997, 2: 33–39.
  86. Fazekas, T., Vos, M. A., Van der Zande és mtsai: Az interventricularis diszperzió-növekedés szerepe az ibutilid által előidézett monomorf és torsades de pointes kamrai tachycardia kialakulásában. Cardiol. Hung., 1999, 4: 159–168.
  87. Ferencz, Gy., Andrássy, G., Trummer, Zs. és mtsai: Hypoparathyreosis, hypokalaemia, hosszú QT-szindróma együttes előfordulása – esetbemutatás. Cardiol. Hung., 2005, 35: B1.
  88. Fernandez, D., Ghanta, A., Kauffman, G. W. et al.: Physico-chemical features of the HERG channel drug binding site. J. Biol. Chem., 2004, 279: 10120–10127.
  89. Fish, J. M., Brugada, J., Antzelevitch, C.: Potential proarrhythmic effects of biventricular pacing. J. Am. Coll. Cardiol., 2005, 46: 2340–2347.
  90. Forster, T., Imre, G., Marosi, Gy. és mtsai: Krónikus urticaria kezelése kapcsán kialakult, sikeresen megszüntetett „torsades de pointes” tachycardia. Bőrgyógy. Vener. Szle, 1984, 60: 273–277.
  91. Fossa, A. A., Depasquale, M. J., Raunig, D. L. et al.: The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J. Pharmacol. Exp. Ther., 2002, 302: 828–833.
  92. Fujimoto, Y., Morita, H., Fukushima, K. K., Ohe, T.: Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome. Heart, 1999, 82: e8.
  93. Fülöp, L., Bányász, T., Szabó, G. et al.: Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol., 2006, 188: 163–171.
  94. Gabel, A., Schymik, G., Mehmel, H. C.: Ventricular fibrillation due to long QT syndrome probably caused by clindamycin. Am. J. Cardiol., 1999, 83: 813–815.
  95. Gidh-Jain, M., Huang, B., Jain, P. et al.: Differential expression of voltage-gated K+ channel genes in left ventricular remodeled myocardium after experimental myocardial infarction. Circ. Res., 1996, 79: 669–675.
  96. Gonzalez, M. M., Cavalcanti, T. C., Vianna, C. B. et al.: Hypomagnesaemia causing QT interval prolongation and torsade de pointes in an alcoholic patient. Resuscitation, 2006, 70: 346–347.
  97. Gottsegen, Gy., Török, E.: Psychogen kamraremegés. Orv. Hetil., 1962, 103: 2361–2365.
  98. Gottsegen, Gy., Török, E.: Psychogenes Kammerflimmern. Dtsch. Med. Wschr., 1962, 87: 2247–2250.
  99. Haigney, M. C., Zareba, W., Gentlesk, P. J. et al.: QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J. Am. Coll. Cardiol., 2004, 44: 1481–1487.
  100. Halkin, A., Roth, A., Lurie, I.: Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J. Am. Coll. Cardiol., 2001, 38: 1168–1174.
  101. Harsányi, A., Préda I., Ács E. et al.: Dramatic effectivity of antialdosterone (Aldactone) treatment in cases of “long QT syndrome” with chaotic ventricular activity. In: Electrocardiology, 1981. Antalóczy, Z., Préda, I. (eds) Akadémiai Kiadó, Budapest, 1982, 597–602.
  102. Hartigan-Go, K., Bateman, D. N., Nyberg, G. et al.: Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin. Pharmacol. Ther., 1996, 60: 543–553.
  103. Hassaballa, H. A., Balk, R. A.: Torsade de pointes associated with the administration of intravenous haloperidol. Am. J. Ther., 2003, 10: 58–60.
  104. Haverkamp, W., Breithardt, G., Camm, J. A. et al.: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implication report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res., 2000, 47: 219–33.
  105. Hii, J. T. Y., Wyse, D. G., Gillis, A. M. et al.: Precordial QT interval dispersion as a marker of Torsade de Pointes. Disparate effects of Class Ia antiarrhythmic drugs and amiodarone. Circulation, 1992, 86: 1376–1382.
  106. Hii, J. T. Y., Wyse, D. G., Gillis, A. M. et al.: Propafenone-induced Torsade de Pointes: Cross-reactivity with quinidine. Pacing Clin. Electrophysiol., 1991, 14: 1568–1570.
  107. Hoehns, J.D., Stanford, R.H., Geraets, D.R. et al.: Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy, 2001, 21: 871–883.
  108. Hoffmann, A.: Fibrillation of the ventricle at the end of an attack of paroxysmal tachycardia in man. Heart, 1911/1912, 3/4 (issued Febr 8, 1912): 213–217.
  109. Hohnloser, S. H., Klingenheben, T., Singh, B. N.: Amiodarone-associated proarrhythmic effects. A review with special reference to Torsade de Pointes tachycardia. Ann. Intern. Med., 1994, 121: 529–535.
  110. Honig, P. K., Woosley, R. L., Zamani, K. et al.: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther., 1992, 52: 231–238.
  111. Hsieh, M. B., Chen, S. A., Chiang, C. E. et al.: Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int. J. Cardiol., 1996, 54: 85–88.
  112. Indik, J. H., Pearson, E. C., Fried, K. et al.: Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm., 2006, 3: 1003–1007.
  113. Ishida, S., Takahashi, N., Nakagawa, M. et al.: Relation between QT and RR intervals in patients with bradyarrhythmias. Br. Heart J., 1995, 74: 159–162.
  114. Jackman, W. M., Friday, K. J., Anderson, J. L. et al.: The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Progr. Cardiovasc. Dis., 1988, 31: 115–172.
  115. Janse, M. J.: Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc. Res., 2004, 61: 208–217.
  116. Janse, M. J., Sosunov, E. A., Coronel, R. et al.: Repolarization gradients in the canine left ventricle before and after induction of short-term cardiac memory. Circulation, 2005, 112: 1711–1718.
  117. January, C. T., Makielski, J. C.: Proarrhythmia related to prolongation of repolarization: mechanisms, monitoring, prevention, and management. CEPR, 2000, 4: 212–216.
  118. January, C. T., Riddle, J. M., Salata, J. J.: A model for early afterdepolarizations: Induction with the Ca2+-channel agonist Bay K 8644. Circ. Res., 1988, 62: 563–571.
  119. Jermendy, Gy., Tóth, L., Vörös, P. et al.: Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients. Acta Cardiol., 1991, 46: 189–200.
  120. Jo, S. H., Youm, J. B., Lee, C. O. et al.: Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline. Br. J. Pharmacol., 2000, 129: 1474–1480.
  121. Jost, N., Papp, J. Gy., Varró, A.: Slow delayed rectifier potassium current (IKs) and the repolarization reserve. Ann. Noninvasive Electrocardiol., 2007, 12: 64–78.
  122. Jost, N., Virág, L., Bitay, M. et al.: Restricting excessive cardiac action potential and QT prolongation. Circulation, 2005, 112: 1392–1399.
  123. Justo, D., Zeltser, D.: Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses, 2006, 49: 463–470.
  124. Kääb, S.: Potassium in long QT syndromes. Heart Drug., 2005, 5: 51–53.
  125. Kääb, S., Hinterseer, M., Näbauer, M. et al.: Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome – a case-control pilot study using i.v. sotalol. Eur. Heart J., 2003, 24: 649–657.
  126. Kadish, A. H., Weisman, H. F., Veltri, E. P. et al.: Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type Ia antiarrhythmic agents. Circulation, 1990, 81:14–19.
  127. Kang, J., Wang, L., Chen, X. L. et al.: Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol., 2001, 59: 122–126.
  128. Kannankeril, P. J., Roden, D. M.: Drug induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol., 2007, 22: 39–43.
  129. Kannankeril, P. J., Roden, D. M., Norris, K. J. et al.: Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm, 2005, 2: 134–140.
  130. Katritsis, D., Camm, A. J.: Quinolones: cardioprotective or cardiotoxic? Pacing Clin. Electrophysiol., 2003, 26: 2317–2320.
  131. Kaye, P., O’Sullivan, I.: The role of magnesium in the emergency department. Emerg. Med. J., 2002, 19: 288–291.
  132. Kecskeméti, V., Pacher, P.: Fluoxetine: an SSRI and effective ion (calcium)-channel antagonist. Neuropsychopharmacol. Hung., 2002, 4: 197–206.
  133. Kempler, P., Hermányi, Zs., Marton, A. és mtsai: Autonom neuropathia és a QT-távolság megnyúlása frissen felfedezett inzulindependens diabetes mellitusban. Magy. Belorv. Arch., 1999, 52: 147–151.
  134. Kilborn, M. J.: Determination of QT response phenotype with low-dose ibutilide. AHA Congress, Circulation, 2000, II-673: 3254A.
  135. Kiss, Z., Fazekas, T.: Arrhythmias in organophosphate poisonings. Acta Cardiol. 1979, 34: 323–330.
  136. Kiss, Z., Fazekas, T.: Organophosphates and torsade de pointes ventricular tachycardia. J. Royal Soc. Med., 1983, 76: 984–985.
  137. Kiss, Z., Fazekas, T.: Szívritmuszavarok báriummérgezésben. Magy. Belorv. Arch. 1979, 32: 297–303.
  138. Kozhevnikov, D. O., Yamamoto, K., Robotis, D.: Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation, 2002, 105: 1128–1134.
  139. Kulan, K., Komsuoglu, B., Tuncer, C. et al.: Significance of QT dispersion on ventricular arrhythmias in mitral valve prolapse. Int. J. Cardiol., 1996, 54: 251–257
  140. Kurita, T., Ohe, T., Marui, N. et al.: Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with Torsades de Pointes. Am. J. Cardiol., 1992, 69: 628–633.
  141. Kuryshev, Y. A., Ficker, E., Wang, L. et al.: Pentamidin-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther., 2005, 312: 316–323.
  142. Lankipalli, R. L., Zhu, T., Guo, D. et al.: Mechanisms underlying arrhythmogenesis in long QT syndrome. J. Electrocardiol., 2005, 38: 69–73.
  143. Lawrence, K. R., Nasraway, S. A.: Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy, 1997, 17: 531–537.
  144. Lazzara, R.: Cellular basis for the U wave and its translation to the surface ECG. J. Electrocardiol., 1991, 24: S44–545.
  145. Lee, S. Y., Choi, S. Y., Youm, J. B. et al.: Block of HERG human K+ channel and IKr of guinea pig cardiomyocytes by chlorpromazine. J. Cardiovasc. Pharmacol., 2004, 43: 706–714.
  146. Leenhardt, A., Coumel, Ph., Slama, R.: Torsades de pointes. J. Cardiovasc. Electrophysiol., 1992, 3: 281–292.
  147. Lehmann, M. H., Hardy, S., Archibald, D. et al.: Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation, 1996, 94: 2535–2541.
  148. Lehtonen, A., Fodstad, H., Laitinen-Forsblom, P. et al.: Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm, 2007, 4: 603–607.
  149. Lengyel, Cs., Dézsi, M., Biliczki, P. et al.: Effect of a neuroprotective drug, eliprodil on cardiac repolarization: importance of the decreased repolarization reserve in the development of proarrhythmic risk. Br. J. Pharmacol., 2004, 143: 152–158.
  150. Lengyel, Cs., Jost, N., Virág, L. és mtsai: A késői egyenirányító kálium áram lassú komponensének (IKs) blokkolása, a gyors komponens (IKr) gátlásával ellentétben, nem nyújtja meg a kamrai repolarizációt nyúlszív preparátumokon. Cardiol. Hung., 2001, 30: 193–202.
  151. Lengyel, Cs., Jost, N., Virág, L. et al.: Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration. Br. J. Pharmacol., 2001, 132: 101–110.
  152. Lengyel, Cs., Thury, A., Várkonyi, T. és mtsai: A szívfrekvencia-variabilitás valamint a QT-intervallum térbeli és cirkadián diszperziójának vizsgálata diabéteszes autonom neuropathiában. Magy. Belorv. Arch., 1997, 50: 431–438.
  153. Lengyel, Cs., Várkonyi, T., Fazekas, T.: Erythromycin által előidézett „torsades de pointes” kamrai tachycardia. Orv. Hetil., 1997, 138: 1003–1006.
  154. Lengyel, Cs., Várkonyi, T. T., Boda, K., Fazekas, T.: QT szakasz diszperzió-növekedés cukorbetegségben. Orv. Hetil., 1997, 138: 337–341.
  155. Lengyel, Cs., Varró, A., Tábori, K. et al.: Combined pharmacological block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes. Br. J. Pharmacol., 2007, 151: 941–951.
  156. Lengyel, Cs., Virág, L., Bíró, T. et al.: Diabetes mellitus attenuates the repolarization reserve in mammalian heart. Cardiovasc. Res., 2007, 73: 512–520.
  157. Lengyel, Cs., Virág, L., Kovács, P.P. et al.: Role of slow delayed rectifier K+-current in QT prolongation in the alloxan-induced diabetic rabbit heart. Acta Physiol., 2008, 192: 359–368.
  158. Lin, C., Ke, X., Cvetanovic, I. et al.: The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Cardiology, 2007, 108: 18–27.
  159. Linder, J. A., Huang, E. S., Dteinman, M. A. et al.: Fluoroquinolone prescribing in the United States: 1995-2002. Am. J. Med., 2005,118: 259–268.
  160. Lindquist, M., Edwards, I. R.: Risks of non-sedating antihistamines. Lancet., 1997, 349: 1322.
  161. Liszkai, G., Fazekas, T.: Tranziens ischaemiás attak képében jelentkező kinidin-syncope. Orv. Hetil., 1998, 139: 1425–1428.
  162. Little, R. E. et al.: Torsade de Pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin. Electrophysiol., 1990, 13: 164–170.
  163. Liu, D. W., Antzelevitch, C.: Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial and endocardial myocytes: a weaker IKs contributes to the longer action potential of the M cell. Circ. Res., 1995, 76: 351–365.
  164. Liu, K., Yang, T., Viswanathan, P. C.: New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation, 2005, 112: 3239–3246.
  165. Llerena, A., Berecz, R., de la Rubia, A., Dorado, P.: QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol., 2002, 16: 361–364.
  166. Locati, E. H.: Torsades de pointes. In: Noninvasive Electrocardiology. Clinical Aspects of Holter Monitoring. Moss, A. J., Stern, S. (eds) WB Saunders Co., London, 1996, 59–72.
  167. Locati, E. H., Maison-Blanche, P., Dejode, P. et al.: Spontaneous sequences of onset of Torsade de Pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J. Am. Coll. Cardiol., 1995, 25: 1564–1575.
  168. Lopez, J. A., Harold, J. G., Rosenthal, M. C. et al.: QT prolongation and Torsades de Pointes after administration of trimethoprim sulfamethoxazole. Am. J. Med., 1987, 59: 376–377.
  169. Magyar, J., Szentandrássy, N., Bányász, T. et al.: Effects of thymol on calcium and potassium currents in canine and human ventricular cardiomyocytes. Br. J. Pharmacol., 2002, 136: 330–338.
  170. Maison-Blanche, P., Catuli, D., Fayn, J. et al.: QT interval, heart rate and ventricular arrhythmias. In: Noninvasive Electrocardiology. Clinical Aspects of Holter Monitoring. Moss, A. J., Stern, S. (eds) WB Saunders Co., London, etc., 1996, 383–404.
  171. Makai, A., Rudas, L., Liszkai, G., Fazekas, T.: Intravénás amiodaron által előidézett torsades de pointes kamrai tachycardia. Orv. Hetil., 2003, 144: 241–247.
  172. Makita, N., Horie, M., Nakamura, T. et al.: Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation, 2002, 106: 1269–1274.
  173. Martinez, J. B., Moos, D. D., Dahlen, L. L.: Droperidol’s effect on QT interval. J. Perianesth. Nurs., 2006, 21: 82–87.
  174. Mattioni, T. A., Zheutlin, T. A., Sarmiento, J. J. et al.: Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann. Intern. Med., 1989, 111: 574–580.
  175. Mazur, A., Roden, D. M., Anderson, M. E.: Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation , 1999, 100: 2437–2442.
  176. McLaughlin, N. B., Campbell, R. W., Murray, A.: Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects. Heart, 1996, 76: 422–426.
  177. Medina-Ravell, V. A., Lankipalli, R. S., Yan, G. X.: Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation, 2003, 107: 740–746.
  178. Merkely, B. és mtsai: Művi bradycardia hatása az endothelin okozta kamrai ritmuszavarra kutyán. Cardiol. Hung., 1996, 25/1: 56–58.
  179. Merkely, B., Gellér, L., Tóth, M. et al.: Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs. J. Cardiovasc. Pharmacol., 1998, 31(Suppl.1): S437–S439.
  180. Merkely, B., Tomcsányi, J., Tenczer, J. és mtsai: Monofázisos akciós potenciál-regisztrálás klinikai jelentősége hosszú QT szindrómában. Orv. Hetil., 1996, 137: 283–286.
  181. Milberg, P., Reinsch, N., Osada, N.: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res. Cardiol., 2005, 100: 365–371.
  182. Morganroth, J., Brown, A. M., Critz, S. et al.: Variability of the QT interval: Impact on defining drug effect and low-frequency cardiac event. Am. J. Cardiol., 1993, 72: 26B–31B.
  183. Napolitano, C., Schwartz, P. J., Brown, A. M. et al.: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol., 2000, 11: 691–696.
  184. Nielsen-Kudsk, J. E., Boesgaard, S., Aldershile, J.: K+-channel opening: A new principle in cardiovascular medicine. Heart, 1996, 76: 109–116.
  185. Opthof, T., Coronel, R., Wilms-Schopman, F. J. et al.: Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm, 2007, 4: 341–348.
  186. Pacher, P., Kecskeméti, V.: A szelektív szerotonin-visszavételt gátló antidepresszánsok cardiovascularis hatásai. Orv. Hetil., 2004, 145: 425–431.
  187. Pacher, P., Magyar, J., Szigligeti, P. et al.: Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 361: 67–73.
  188. Paulussen, A. D., Gilissen, R. A., Armstrong, M. et al.: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. Mol. Med., 2004, 82: 182–188.
  189. Pedersen, H. S., Elming, H., Seibaek, M. et al.: Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am. J. Cardiol., 2007, 100: 876–880.
  190. Pinski, S. L., Eguía, L. E., Trohman, R. G.: What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin. Electrophysiol., 2002, 25: 1612–1615.
  191. Pintér, A., Dorian, P., Newman, D.: Cesium-induced torsades de pointes. N. Engl. J. Med., 2002, 346: 383–384.
  192. Pinto, Y. M., van Gelder, I. C., Heeringa, M. et al.: QT lengthening and life-threatening arrhythmias associated with fexofenadin. Lancet., 1999, 353: 980.
  193. Piquette, R. K.: Torsade de pointes induced by cisapride/clarithromycin interaction. Ann. Pharmacother., 1999, 33: 22–26.
  194. Pourmoghaddas, A., Hekmatnia, A.: The relationship between QTc interval and cardiac autonomic neuropathy in diabetes mellitus. Mol. Cell. Biochem., 2003, 249: 125–128.
  195. Préda, I., Mózer, I.: Klinikai megfigyelések accidentalis hypothermiában. Orv. Hetil., 1974, 115: 1936–1940.
  196. Quek, D. K., Hang, P. K.: Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea – a case report. Singapore Med. J., 1993, 34: 266–270.
  197. Ramee, White, C. J., Svinarich, J. T. et al.: Torsade de pointes and magnesium deficiency. Am. Heart J., 1985, 109: 164–167.
  198. Ray, W. A., Meredith, S., Thapa, P. B.: Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry, 2001, 58: 1161–1167.
  199. Ray, W. A., Murray, K. T., Meredith, S. et al.: Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med., 2004, 351: 1089–1096.
  200. Remme, C. A., Bezzina, C. R.: Genetic modulation of cardiac repolarization reserve. Heart Rhythm, 2007, 4: 608–610.
  201. Rizza, C., Valderrabano, M., Singh, B. N.: Recurrent Torsades de Pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease. J. Cardiovasc. Pharmacol. Ther., 1999, 4: 129–134.
  202. Roden, D. M.: Drug-induced prolongation of the QT interval. N. Engl. J. Med., 2004, 350: 1013–1022.
  203. Roden, D. M.: Taking the “idio” out of “idiosyncratic”: Predicting torsades de pointes. Pacing Clin. Electrophysiol., 1998, 21: 1029–1034.
  204. Roden, D., Kannankeril, P., Darbar, D.: On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace. Suppl., 2007, 4: iv1–3.
  205. Roden, D. M., Viswanathan, P. C.: Genetics of acquired long QT syndrome. J. Clin. Invest., 2005, 115: 2025–2032.
  206. Roden, D. M., Woosley, R. L., Primm, R. K.: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am. Heart J. 1986, 111: 1088–1093.
  207. Roden, D. M., Yang, T.: Protecting the heart against arrhythmias: potassium current physiology and repolarization. Circulation, 2005, 112: 1378–1378.
  208. Rosen, M. R., Jeck, C. D., Steinberg, S. F.: Autonomic modulation of cellular repolarization and of the electrocardiographic QT interval. J. Cardiovasc. Electrophysiol., 1992, 3: 487–499.
  209. Roy. M. L., Dumaine, R., Brown, A. M.: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation, 1996, 94: 817–823.
  210. Rudas, L., Szabados, S., Gaál, T.: Teljes AV-blokk szövődése „torsades de pointes” kamrai tahikardiával pacemaker beültetés során. Orv. Hetil., 1984, 125: 89–91.
  211. Ruszty, L., Böröcz, P.: Vinpocetin- (Cavinton-) kezelés és a proarrhythmiák veszélye. Gyógyszereink, 2003, 53: 9–16.
  212. Sato, T., Hata, Y., Yamamoto, M. et al.: Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J. Cardiovasc. Electrophysiol., 1995, 6: 279–282.
  213. Satoh, T., Zipes, D. P.: Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation, 1996, 94: 217–227.
  214. Sawicki, P. T., Dähne, R., Bender, R. et al.: Prolonged QT intervals as a predictor of mortality in diabetic neuropathy. Diabetologia, 1996, 39: 77–81.
  215. Schenck, J. B., Rizvi, A. A., Lin, T.: Severe primary hypothyroidism manifesting with torsades de pointes. Am. J. Med. Sci., 2006, 331: 154–156.
  216. Scherlag, B. J., Szabó, B., Patterson, E. et al.: Cesium-induced early afterdepolarizations and triggered activity in intact animals and isolated tissues. In: Cardiac Electrophysiology: A Textbook. Rosen, M. R., Janse, M. J., Wit, A. L. (eds) Futura Publishing Co., Armonk, NY, 1990, 355–370.
  217. Schwarz, S. P., Halliger, L. N.: Transient ventricular fibrillation. VI. Observations on the peripheral arterial pulse pressures in the course of transient ventricular fibrillation during established auriculoventricular dissociation. Am. Heart J., 1954, 48: 390–404.
  218. Schwoerer, A. P., Blutner, C., Brandt, S. et al.: Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization. Anesthesiology, 2007, 106: 967–976.
  219. Seltzer, A., Wray, H. W.: Quinidine syncope. Paroxysmal ventricular fibrillation occuring during treatment of chronic atrial arrhythmias. Circulation, 1964, 30: 17–26.
  220. Shah, A., Schwarz, H.: Mexiletine for treatment of torsade de pointes. Am. Heart J., 1984, 107: 589–591.
  221. Shah, R. R.: Drug-induced prolongation of the QT interval: why the regulatory concern? Fund. Clin. Pharmacol., 2002, 16: 119–124.
  222. Shah, R. R.: Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann. Med., 2004, 36(Suppl. 1): 47–52.
  223. Sharma, N. D., Rosman, H. S., Padhim, I. D., Tisdale, J. E.: Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiol., 1998, 81: 238–240.
  224. Sharma, P. P., Sarma, J. S. M., Singh, B. N.: Effects of sotalol on the circadian rhythmicity of heart rate and QT intervals with a noninvasive index of reverse-use dependency. J. Cardiovasc. Pharmacol. Ther., 1999, 4: 15–21.
  225. Shimizu, W., Antzelevitch, C.: Cellular and ionic basis for T-wave alternans under long QT conditions. Circulation, 1999, 10: 244–260.
  226. Shimizu, W., Tanaka, K., Suenaga, K. et al.: Bradycardia-dependent early afterdepolarizations in a patient with QTU prolongation and Torsade de Pointes in association with marked bradycardia and hypokalaemia. Pacing Clin. Electrophysiol., 1991, 14: 1105–1111.
  227. Sicouri, S., Timothy, K. W., Zygmunt, A. C. et al.: Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm, 2007, 4: 638–647.
  228. Singh, S. N., Lazin, A., Cohen, A. et al.: Sotalol-induced torsades de pointes sucessfully treated with hemodialysis after failure of conventional therapy. Am. Heart J., 1991, 121: 601–602.
  229. Sivieri, R., Veglio, M., Chinaglia, A.: Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes. Diabet. Med., 1993, 10: 920–924.
  230. Solti, F., Czakó, E., Juwancz, P.: The effect of Cavinton on impulse fonnation and impulse conduction of the heart. Ther. Hung., 1983, 31: 24–25.
  231. Solti, F., Szatmáry, L., Vecsey, T. et al.: Congenital complete heart block associated with QT prolongation. Eur. Heart J., 1992, 13: 1080–1083.
  232. Solti, F., Szatmáry, L., Vecsey, T. et al.: Characteristics of long QT with permanent bradycardia. Acta Med. Hung., 1994, 50: 33–42.
  233. Splawski, I., Timothy, K. W., Sharpe, L. M. et al.: Ca(v)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell, 2994, 119: 19–31.
  234. Splawski, I., Timothy, K. W., Tateyama, M.: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science, 2002, 297: 1333–1336.
  235. Stramba-Badiale, M., Nador, F., Porta, N. et al.: QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am. Heart J., 1997, 133: 108–111.
  236. Straus, S. M., Sturkenboom, M. C., Bleumink, G. S. et al.: Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J., 2005, 26: 2007–2012.
  237. Studenik, C., Lemmens-Gruber, R., Heistracher, P.: Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur. J. Pharm. Sci., 1999, 7: 113–118.
  238. Szabó, B., Kovács, T., Lazzara, R.: Role of calcium loading in early afterdepolarizations generated by Cs++ in canine and guinea pig Purkinje fibers. J. Cardiovasc. Electrophysiol., 1995, 6: 796–812.
  239. Takács, J., Jost, N., Lengyel, C. et al.: Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations. Eur. J. Pharmacol., 2003, 470: 163–170.
  240. Takanaka, C., Ogunyankin, K. O., Sarma, J. S., Singh, B. N.: Antiarrhythmic and arrhythmogenic actions of varying levels of extracellular magnesium: Possible cellular basis for the differences in the efficacy of magnesium and lidocaine in Torsade de Pointes. J. Cardiovasc. Pharmacol. Ther., 1997, 2: 125–134.
  241. Takenaka, I., Aoyama, K., Iwagaki, T.: Development of torsade de pointes caused by exacerbation of QT prolongation during clipping of cerebral artery aneurysm in a patient with subarachnoid haemorrhage. Br. J. Anaesth., 2006, 97: 533–535.
  242. Taylor, G. J., Crampton, R. S., Gibson, R. S.: Prolonged QT interval at onset of acute myocardial infarction in predicting early phase ventricular tachycardia. Am. Heart J., 1981, 102: 16–24.
  243. Teschemacher, A. G., Seward, E. P., Hancox, J. C.: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br. J. Pharmacol., 1999, 128: 479–85.
  244. Thomas, D., Gut, B., Wendt-Nordahl, G. et al.: The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J. Pharmacol. Exp. Therap., 2002, 300: 543–548.
  245. Thomas, M., Maconochie, J. G., Fletcher, E.: The dilemma of the prolonged QT interval in early drug studies. Br. J. Clin. Pharmacol., 1996, 41: 77–81.
  246. Thomsen, M. B., Verduyn, S. C., Stengl, M. et al.: Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation, 2004, 110: 2453–2459.
  247. Tomaselli, G. F., Marban, E.: Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc. Res., 1999, 42: 270–283.
  248. Tomcsányi, J., Arabazisz, H., Bózsik, B. és mtsai: Reverzíbilis systolés balkamra-diszfunkció pszichés stressz hatására: tako-tsubo-szindróma. Cardiol. Hung., 2005, 35: 160–162.
  249. Tomcsányi, J., Somlói, M., Frész, T. és mtsai: Agyvérzést követő T-hullám alternans és torsade de pointes kamrai tachycardia. Orv. Hetil., 2003, 144: 2077–2079.
  250. Topilski, I., Rogowski, O., Rosso, R.: The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J. Am. Coll. Cardiol., 2007, 49: 320–328.
  251. Tosiello, L.: Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch. Intern. Med., 1996, 156: 1143–1148.
  252. Tóth, M., Solti, F., Merkely, B. et al.: Ventricular tachycardia induced by intracoronary administration of endothelin-1 in dogs. J. Cardiovasc. Pharmacol., 1995, 26 (Suppl 3): 153–155.
  253. Tsuchihashi, K., Ueshima, K., Uchida, T. et al.: Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J. Am. Coll. Cardiol., 2001, 38: 11–18.
  254. Tsuji, Y., Opthof, T., Yasui, K.: Ionic mechanisms of acquired QT prolongation and torsades de pointes in rabbits with chronic complete atrioventricular block. Circulation, 2002, 106: 2012–2028.
  255. Turitto, G., Haq, S., Benson, D.: Torsade de pointes: an electrophysiological effect of cardiac resynchronization? Pacing Clin. Electrophysiol., 2006, 29: 520–522.
  256. Tzivoni, D., Keren, A., Cohen, A. M. et al.: Magnesium therapy for Torsades de Pointes. Am. J. Cardiol., 1984, 53: 528–530.
  257. Van der Zande, J., Vos, M. A., Fazekas, T. et al.: The dose-dependent inerease in interventricular dispersion of repolarization after ibutilide causes the transition from repetitive ectopic beats to torsade de pointes arrhythmias. Eur. Heart J., 1996, 17: 596A.
  258. Vandermotten, M., Verhaeghe, R., De Geest, H.: Ventricular arrhythmias and QT-prolongation during therapy with ketanserin. Report of a case. Acta Cardiol., 1989, 5: 431–437.
  259. Varró, A., Baláti, B., Jost, N. et al.: The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol., 2000, 523: 67–81.
  260. Varró, A., Fazekas, T., Papp, Gy.: Amiodaron – 1994. Cardiol. Hung., 1995, 24(1): 5–17.
  261. Varró, A., Papp, J. Gy.: Low penetrance, subclinical congenital LQTS: concealed LQTS or silent LQTS? Cardiovasc. Res., 2006, 70: 404–406.
  262. Verduyn, S. C., Vos, M. A., Gorgels, A. P. et al.: The effect of flunarizine and ryanodine on acquired Torsades de Pointes arrhythmias in the intact canine heart. J. Cardiovasc. Electrophysiol., 1995, 6: 189–200.
  263. Virág, L., Fazekas, T., Jost, N. et al.: Effect of GLG-V-13, a class III antiarrhythmic agent, on potassium currents in rabbit ventricular myocytes. Life Sci., 2000, 66: 253–258.
  264. Viskin, S.: Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J. Cardiovasc. Electrophysiol., 2000, 11: 593–600.
  265. Viskin, S., Justo, D., Halkin, A. et al.: Long QT syndrome caused by noncardiac drugs. Prog. Cardiovasc. Dis., 2003, 45: 415–427.
  266. Volberg, W. A., Koci, B. J., Su, W.: Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther., 2002, 302: 320–327.
  267. Volders, P. G., Sipido, K. R., Vos, M. A. et al.: Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation, 1999, 100: 2455–2461.
  268. Volders, P. G., Stengl, M., van Opstal, J. M. et al.: Probing the contribution of IKs to canine ventricular repolarization. Key role for β-adrenergic receptor stimulation. Circulation, 2003, 107: 2753–2760.
  269. Volders, P. G., Vos, M. A., Szabo, B. et al.: Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc. Res., 2000, 46: 376–392.
  270. Vos, M. A., Fazekas, T., Gorgels, A. P. et al.: Action of MgSO4 differs from moricizine and verapamil on ouabain-induced ventricular tachycardias in normomagnesemic conscious dogs. J. Cardiovasc. Pharmacol., 1994, 23: 252–258.
  271. Vos, M. A., Gorenek, B., Verduyn, S. C. et al.: Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc. Res., 2000, 48: 421–429.
  272. Vos, M. A., Gorgels, A. P., Lipcsei, G. C. et al.: Mechanism-specific antiarrhythmic effects of the potassium channel activator levcromakalim against repolarization-dependent tachycardias. J. Cardiovasc. Electrophysiol., 1994, 5: 731–742.
  273. Vos, M. A., van Opstal, J. M., Leunissen, J. D. M. et al.: Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol. Ther., 2001, 92: 109–122.
  274. Vos, M. A., Verduyn, S. C., Gorgels, A. P. et al.: Reproducible induction of early afterdepolarizations and Torsade de Pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation, 1995, 91: 864–872.
  275. Waldo, A. L. et al. for the SWORD investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet., 1996, 348: 7–12.
  276. Weissenburger, J., Davy, J-M., Chézalviel, F.: Experimental models of torsades de pointes. Fund. Clin. Pharmacol., 1993, 7: 29–38.
  277. Wesley, R. C., Turnquest, P.: Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome. Am. Heart J., 1992, 123: 794–796.
  278. 278. Witchel, H. J., Pabbathi, V. K., Hofmann, G. et al.: Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett., 2002, 512: 59–66.
  279. Woosley, R. L.: Drugs that prolong the QTc interval and/or induce Torsade de Pointes. link
  280. Wu, L., Shryock, J. C., Song, Y., Li, Y. et al.: Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J. Pharmacol. Exp. Ther., 2004, 310: 599–605.
  281. Wu, Y. S. J. et al.: Role of Purkinje fibers in induction of early afterdepolarizations and triggered ventricular tachycardia in isolated rabbit hearts. J. Am. Coll. Cardiol., 1996, 28: 208A.
  282. Xue, Q., Reddy, S.: Algorithms for computerized QT-analysis. J. Electrocardiol., 1998, 30: 181–186.
  283. Yamaguchi, M., Shimizu, M., Ino, H. et al.: T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin. Sci., 2003, 105: 671–676.
  284. Yan, G. X., Antzelevitch, C.: Cellular basis for the electrocardiographic J wave. Circulation, 1996, 93: 372–379.
  285. Yan, G. X., Antzelevitch, C.: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation, 1998, 98: 1928–1936.
  286. Yang, P., Kanki, H., Drolet, B. et al.: Allelic variants in long-QT disease genes in patients with drug-induced torsades de pointes. Circulation, 2002, 105: 1943–1948.
  287. Zhang, L., Timothy, K. W., Antzelevitch, C. et al.: Cardiac L-type channel mutations caused the longest QT interval compared to the common genotypes of long QT syndrome. Circulation, 2005, II-701.
  288. Zhou, J. T., Zheng, L. R., Liu, W. J. et al.: Early afterdepolarizations in the familial long QTU syndrome. J. Cardiovasc. Electrophysiol., 1992, 3:431–436.
  289. Zipes, D. P., Camm, A. J., Borggrefe, M. et al.: ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J., 2006, 27: 2099–2140.
  290. Züchner, H.: QT-Verlängerung und Torsade de pointes-Tachykardie bei Therapie mit Maprotilin. Dtsch. Med. Wschr. schr., 2002, 127: 983–984.
  291. Zygmunt, A. C., Eddlestone, G. T., Thomas, G. P. et al.: Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am. J. Physiol., 2001, 281: H689–H697.
  292. Zygmunt, A. C., Goodrow, R. J., Antzelevitch, C.: INa-Ca contributes to electrical heterogeneity within the canine ventricle. Am. J. Physiol., 2000, 278: H1671–H1678.

Klinikai szív-elektrofiziológia és aritmológia

Tartalomjegyzék


Kiadó: Akadémiai Kiadó

Online megjelenés éve: 2016

ISBN: 978 963 059 748 7

A Klinikai szív-elektrofiziológia és aritmológia első kiadását a szívritmuszavarok patofiziológiájában, farmakológiájában, diagnosztikájában és gyógyításában kiemelkedően jártas hazai szakírók vetették papírra. Az aritmiában szenvedő betegek optimális ellátásához nélkülözhetetlen, az idő tájt rendelkezésre álló elméleti és klinikai tudnivalókat átfogóan ismertető kézikönyv iránti olvasói érdeklődés és a Magyar Tudományos Akadémia Orvosi Osztályának Nívódíja bizonyította, hogy a szerzők és a szerkesztők erőfeszítései nem voltak haszontalanok. Egy évtized az élettudományok fejlődésének jelenlegi tempóját figyelembe véve nagyon hosszú idő. Az elektrofiziológia és (a)ritmológia mind a mai napig a szívgyógyászat egyik legdinamikusabban fejlődő technicizálódó ága, melynek vertikuma egyre nagyobb: a szívizom szabályos ritmikáját megzavaró, nemritkán öröklődő patobiokémiai eltérések felismerésétől az új típusú, innovatív gyógyszerek hozzáértő alkalmazásán keresztül az egyre kifinomultabb invazív terápiás eljárásokig ível. Ennélfogva idő- és szükségszerűvé vált a lényegbevágóan új diagnosztikai / képalkotó módszerek, gyógyszeres és instrumentális kezelési módozatok, valamint a nagy mintaszámú, randomizált, kontrollcsoportos arrhythmiavizsgálatok eredményein nyugvó és a szakmai tudományos irányelvek főbb útmutatásait visszatükröző ismeretek friss, kézikönyvbe foglalt szintézise: a tudományág fejlődésével lépést tartó jelen, második, új fejezetek beépítésével és a régebbiek újraírásával, felülvizsgálatával gazdagított kiadás megírása, összeállítása.

Hivatkozás: https://mersz.hu/fazekas-merkely-papp-tenczer-klinikai-sziv-elektrofiziologia-es-aritmologia//

BibTeXEndNoteMendeleyZotero

Kivonat
fullscreenclose
printsave